Novartis told the court in a separate filing on Friday that India-based MSN may receive U.S. Food and Drug Administration approval for the generic as soon as July 16 and launch it soon after. The ...

Johnson & Johnson convinced a U.S. appeals court on Tuesday to reject a bid from generic drugmakers Teva and Viatris to invalidate a patent covering its schizophrenia medication Invega Sustenna.